What pandemic? Biotech floats break records
After a brief pause in the first quarter flotations have come flooding back, with drug developers raising almost $5bn so far this year.
Biopharma venture investors shrug off Covid-19
First-quarter venture investments barely register the pandemic - huge cash reserves should protect funding for biotech start-ups this year.
Another venture funding surge sets up a strong 2018
Cell and gene therapy companies dominate the first quarter, but companies outside these fashionable areas are finding it harder to charm VCs.
